CW November 2004
Volume 13Issue Number 11 November 2004 ISSN 10593802 Gefitinib/FOLFOX-6s in First-Line Metastatic Colorectal CancerA preliminary study investigating the efficacy and tolerability of the first-line combination of gefitinib (Iressa, AstraZeneca) in combination with a simplified FOLFOX-6 regimen shows promise in patients with advanced colorectal cancer. Presented at the 29th European Society of Medical Oncology Congress, Vienna, Austria.
Go to Previous Page Go to Next Page Source & Additional Reading Presented at the 29th European Society of Medical Oncology Congress, Vienna, Austria. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW November 2004Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
